Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 686 | 68 | 550 |
| Samples | 304 | 43 | 252 |
| Peptides | 267 | 38 | 217 |
Function
CCN4 · Cellular communication network factor 4
This gene encodes a member of the WNT1 inducible signaling pathway (WISP) protein subfamily, which belongs to the connective tissue growth factor (CTGF) family. WNT1 is a member of a family of cysteine-rich, glycosylated signaling proteins that mediate diverse developmental processes. The CTGF family members are characterized by four conserved cysteine-rich domains: insulin-like growth factor-binding domain, von Willebrand factor type C module, thrombospondin domain and C-terminal cystine knot-like domain. This gene may be downstream in the WNT1 signaling pathway that is relevant to malignant transformation. It is expressed at a high level in fibroblast cells, and overexpressed in colon tumors. The encoded protein binds to decorin and biglycan, two members of a family of small leucine-rich proteoglycans present in the extracellular matrix of connective tissue, and possibly prevents the inhibitory activity of decorin and biglycan in tumor cell proliferation. It also attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. It is 83% identical to the mouse protein at the amino acid level. Multiple alternatively spliced transcript variants have been identified. [provided by RefSeq, Mar 2011].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 213 amino-acid changes on canonical ENST00000250160 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CCN4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CCN4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Endometrial Carcinoma | 4/42 10% | 19/612 3% |
| Hodgkins Lymphoma | 0/16 0% | 4/122 3% |
| Melanoma | 3/210 1% | 39/1899 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Gastric Carcinoma | 0/74 0% | 31/1809 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 17/1390 1% |
| Colorectal Carcinoma | 7/143 5% | 32/3239 1% |
| Neuroendocrine Tumour | 5/154 3% | 3/577 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 9/810 1% |
| Ewings Sarcoma | 2/63 3% | 1/262 0% |
| Biliary Tract Carcinoma | 0/54 0% | 9/950 1% |
| Cervical Carcinoma | 1/35 3% | 3/422 1% |
| Adrenocortical Carcinoma | 1/3 33% | 0/112 0% |
| Ovarian Carcinoma | 4/109 4% | 4/998 0% |
| Other Solid Cancers | 1/94 1% | 10/1515 1% |
| Head and Neck Carcinoma | 0/85 0% | 10/1574 1% |
| Pancreatic Carcinoma | 1/89 1% | 8/1611 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 12/2550 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Hepatocellular Carcinoma | 2/46 4% | 6/2210 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Breast Carcinoma | 2/144 1% | 7/3264 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 5/2534 0% |
Mutation Distribution
Where CCN4 is mutated · all tissues, split by cell line vs tissue
How many mutations in CCN4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 686 mutations in CCN4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|